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N. Aaronson, NL
Neil Aaronson, PhD received his undergraduate and graduate training 
at the University of California, Los Angeles. He received his Ph.D. in 
Public Health in 1983. His graduate training was in medical sociology 
and psychiatric epidemiology. He is currently Head of the Department 
of Psychosocial Research, Division of Psychosocial Research and 
Epidemiology at the Netherlands Cancer Institute and Professor in the 
Department of Clinical Psychology at the University of Amsterdam. He 
has served as the chairman of the European Organization for Research and Treatment 
of Cancer Quality of Life Group and as President of the International Society for Quality 
of Life Research. He was the editor-in-chief of the journal Quality of Life Research from 
1999-2005, and currently serves on the editorial board of 6 other professional journals. 
Dr. Aaronson’s primary research interests are in the development of methods for assessing 
health-related quality of life and other patient-reported outcomes, the integration of quality 
of life assessments into clinical trials and clinical practice settings, and the development and 
testing of behavioral and psychosocial interventions in oncology.
P. Kapitein, NL
Peter is President and Patient Advocate of Inspire2Live. He is the 
husband of Marjolijn and father of two sons, Milo and Jaron. Both sportsmen 
and two strong motivations in life for their father. Since 2005, Peter has 
lived with cancer and shown others that cancer does not have to be a death 
sentence, but can also be the start of a new and richer life, full of 
opportunities and beautiful people. Peter is one of the initiators of 
Inspire2Live. What started as an initiative of 66 bikers who on one day 
(6-6-6) cycled up mount Alpe d’Huez six times, is now a huge event raising tens of millions 
each year. A dream, an idea, a target. To transform the most beautiful dream into action. 
The perspective of Peters talks is always that of cooperation between patients, clinicians 
and researchers. Only through this cooperation we will be able to transfer cancer into a 
chronic disease. Peter always inspires his audience and helps them do what they really 
want and what really matters to them. Peter has received an Honorary Doctorate at the 
Free University of Amsterdam.
D. Lacombe, BE
In 1988 Dr. Lacombe graduated as MD from the University of Marseilles 
(France). He was granted for a Master Post-doctoral Fellowship at 
the Roswell Park Cancer Institute, Buffalo, NY, USA for Fundamental 
and Clinical Pharmacokinetics from 1989-1991. From 1991 to 1993 he 
worked as Clinical Research Adviser in charge of the development of a new 
drug in oncology in the pharmaceutical industry. From September 1993 
to January 2013 he has been working as Clinical Research Physician 
at the EORTC in Brussels for various Groups. Until 2007, as Assistant Director Medical 
Affairs, he coordinated the EORTC New Drug Development Team conducting new drug 
development studies. Currently amongst his activities, he is responsible for the Early 
Project Optimization Department dedicated to ensure EORTC studies being in line with 
the EORTC strategy. Since November 2010, he has been appointed as Director HQ of the 
EORTC with main missions being to ensure that the functioning of the EORTC HQ is in line 
with the decisions of the EORTC Board and to develop and coordinate the future EORTC 
Scientific Strategy in accordance with the evolving health care ecosystems.
F. Meunier, BE
Françoise Meunier received her medical degree from the Université Libre 
de Bruxelles (ULB) (magna cum laude) and completed a research fellowship 
at Memorial Sloan-Kettering Cancer Center (New York, 1977-1978, 
Fulbright award). She holds a Master’s Degree in Medical Oncology 
(1976) and Internal Medicine (1979), and a PhD (1985) at the ULB. 
She is certified as Pharmaceutical Medicine specialist (Faculty of 
Pharmaceutical Medicine, UK) as well as in Belgium and she is a Fellow 
of the Royal College of Physicians (UK). As Director General, Françoise Meunier is involved 
in the coordination and administration of all EORTC activities in order to promote the EORTC 
as a major European organization in Cancer Clinical and Translational Research. Françoise 
Meunier is responsible for the organization of scientific activities, public relations and 
medium term strategies as defined by the EORTC Board as well as for internal and external 
the communication. Before joining the EORTC in 1991, Françoise Meunier was Head 
of Infectious Diseases Department at Institute Jules Bordet in Brussels, Belgium and her 
personal area of research included the management of infections in patients with Cancer 
and mainly Invasive Fungal Infections. She has over 150 peer-reviewed published articles. 
Françoise Meunier was awarded the Belgian Laureate “Prix Femmes d’Europe 2004-2005”. 
She is a member of the Belgian Royal Academy of Medicine since 2006. In 2007, she was 
conferred the title of Baroness by His Majesty, The King Albert II of Belgium. She received 
in 2009, the Pezcoller Foundation award as a recognition for her contribution to oncology. 
Since 2011, she is a Fellow of the European Academy of Cancer Sciences. In 2012, 
she became a member of the IMI (Innovative Medicine Initiative) Scientific Committee of 
the European Union. In September 2013, she received the ECCO Life time achievement 
award. In October 2013, she will be awarded a Ben de Pauw Medal for her dedication to 
Medical Mycology, her contribution and support to the EORTC Infectious Diseases Group 
for years.
E.C. Moser, PT
Elizabeth Charlotte (Lotte) Moser (26-3-1973) obtained her medical 
degree (Cum Laude) in 1998 (Amsterdam). She worked in Internal 
medicine and Gynecology in the Netherlands and South Africa (1996-2000). 
She switched from Gynecology to Radiotherapy and worked as a fellow in the 
EORTC (European Organization for Research and Treatment of Cancer) in 
Brussels, Belgium (2002). She received the ASCO Merit Award in 2003 and 
in 2005 ´Steenbergen prijs´ for her publications late effects of Non-Hodgkin´s 
Lymphoma treatment. In 2006 she finished training and left to France. She defended her PhD 
in Leiden in February 2007. During 5 years, she worked in medical clinics in Brest, Quimper 
and Rennes being responsible for radiotherapy and systemic treatment. In 2011, she moved to 
Lisbon, Portugal where she works as an investigator and clinical radiation oncologist at the 
Champalimaud Foundation. She is active member of both Breast and Lymphoma EORTC 
groups and part of the EORTC Taskforce on brain metastases. Since 2012 she is chairing 
the EORTC Survivorship initiative, being a transversal platform across the different tumor 
orientated, radiation oncology and the Quality of Life EORTC groups.
K. Oliver, GB
Kathy Oliver is a founding Co-Director of the International Brain Tumour 
Alliance (IBTA), a worldwide patient organisation focussing on advocacy 
and awareness-raising. She is involved in a range of high-level projects/
committees in Europe addressing brain tumour and rare cancer issues. 
She is a frequent plenary and session speaker at international 
neuro-oncology and cancer conferences. Kathy is Patient Issues Editor 
for the online magazine of the European Association of Neuro-Oncology 
(EANO); a founder member of Rare Cancers Europe; Vice-Chair of the European CanCer 
Organisation Patient Advisory Committee (ECCO PAC); Vice-Chair of the Project Advisory 
Board for the European Patients’ Academy on Therapeutic Innovation (EUPATI); a Director 
of Cancer52 (a UK umbrella organisation for 70 rare cancer charities) and a member of the 
NCRI Brain Tumour Palliative Care and Quality of Life subgroup. Kathy’s son, Colin, was 
diagnosed with a brain tumour in 2004 at age 24 and passed away, at age 32, in August 
2011. She cites her son’s “incredible courage, determination and fortitude” as the driving 
force and inspiration behind her involvement in the international brain tumour and cancer 
community.
 J. Reijneveld, NL
Dr. Jaap Reijneveld is neurologist and staff member at the departments of 
Neurology of the VUmc and the Academic Medical Centre, both situated 
in Amsterdam. At both institutions, he treats patients with primary and 
metastatic brain tumours. Apart from his clinical work, he is involved 
in a number of PhD-projects on underlying mechanisms resulting in 
epilepsy and cognitive disturbances in patients with brain tumours or 
other intracranial lesions. He also is project leader on several projects on 
genomic markers as prognostic and predictive tools in glioma patients. Furthermore, he 
is involved in research projects regarding the value of supportive care of primary brain 
tumour patients and their partners, as well as on (interventions aimed at improvement of) 
health-related quality of life of glioma patients during the end of life phase. Dr. Reijneveld 
is member of the Dutch Society for Neurology (NvN), chairman of the Dutch Society for 
Neuro-Oncology (LWNO), member of the Steering Committee of the Brain Tumour Group, and 
member of the Executive Committee of the Quality of Life Group of the European Organisation 
for Research and Treatment of Cancer (EORTC).
S. Schagen, NL
Sanne Schagen is a group leader in the Division of Psychosocial Research 
and Epidemiology at the Netherlands Cancer Institute in Amsterdam, the 
Netherlands. She is a registered health care psychologist and clinical 
neuropsychologist. Her primary research line is concerned with cognitive 
problems associated with cancer and its treatment. She conducts a range of 
interrelated studies in this area, including neuropsychological examinations, 
the application of brain imaging techniques, experimental animal studies, 
and investigations of the perception and expression of psychosocial symptoms as well as 
interventions to prevent or diminish adverse cognitive symptoms.
R. Stupp, CH
Roger Stupp, M.D. leads the multidisciplinary brain tumor clinic at the 
Department of Neurosurgery of University of Lausanne Medical Center 
(CHUV), Switzerland. For the past four years he has also been the driving 
force for building and developing the Department of Oncology/Hematology 
of the Riviera and Chablais regional hospitals. Recently, Professor Stupp 
was appointed Director of the Zurich Cancer Center and designated 
Director of the Department of Medical Oncology at the University of 
Zurich Hospital, Switzerland. Dr. Stupp is an active and dedicated clinical researcher. His 
special clinical interests include the multimodal management of brain tumors, head and neck 
and lung cancers, new drug development and the association of chemotherapy and radiation 
therapy. He is closely involved in bringing new antiangiogenic and biological treatments to 
the clinic. Roger Stupp is or has been the principal investigator for large multimodality 
clinical trials in brain tumors and non-small cell lung cancer. He serves as President of 
the European Organisation for Research and Treatment of Cancer (EORTC) and the past 
Secretary of the EORTC Brain Tumor Group. Dr. Stupp is an editor for the European Journal 
of Cancer and is a member of several editorial boards including Journal of Clinical Oncology, 
and Neuro-Oncology.
 F. van Leeuwen, NL
In the 1980s Flora van Leeuwen initiated the Epidemiology group of the 
Netherlands Cancer Institute. The epidemiology group has currently 
expanded to 40 employees, and is part of the Division of Psychosocial 
Research and Epidemiology, headed by Flora van Leeuwen. In 1998 
she obtained a Chair in Cancer Epidemiology at The Faculty of Medicine 
from the Vrije UnAiversiteit in Amsterdam. The cancer epidemiology group 
of Flora E. van Leeuwen focuses on two principal research lines: (1) the 
assessment of the long term risks of second malignancy and cardiovascular disease following 
treatment of Hodgkin’s lymphoma, breast cancer, testicular cancer and childhood malignancy 
and (2) the assessment of the roles of and hormone-related and genetic risk factors in the 
etiology of breast and ovarian cancer; Special interest is in late effects of ovarian stimulation 
for in Vitro Fertilization and cancer etiology in BRCA1/2 families. Epidemiologic methods are 
combined with molecular analyses a) to examine gene-environment and gene-treatment 
interactions, and b) to differentiate risk factors for cancer according to specific genetic 
alterations in the tumor. There is extensive experience in the conduct of large-scale cohort 
studies and linkage with disease registries.
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